--- title: "What Is 5-Amino-1MQ? How It Works (And Why Most Dosing Is Wrong) - PeptideSupermarket®" description: "What Is 5-Amino-1MQ? How It Works (And Why Most Dosing Is Wrong)" url: "https://peptidesupermarket.co.uk/research/5-amino-1mq-where-it-fits-how-it-works-and-why-most-dosing-advice-online-doesnt-make-pharmacological-sense" site: "PeptideSupermarket®" country: "United Kingdom" --- [Home](https://peptidesupermarket.co.uk) › [Research](https://peptidesupermarket.co.uk/research) › 5-Amino-1MQ — where it fits, how it works, and why most dosing advice online doesn’t make pharmacological sense [Back to Guides](https://peptidesupermarket.co.uk/research/category/guides) [Guides](https://peptidesupermarket.co.uk/research/category/guides) [5-Amino 1MQ](https://peptidesupermarket.co.uk/research/peptide/5-amino-1mq) # 5-Amino-1MQ — where it fits, how it works, and why most dosing advice online doesn’t make pharmacological sense 5-Amino-1MQ — where it fits, how it works, and why most dosing advice online doesn’t make pharmacological sense Quick take 5-Amino-1MQ is positioned as a small molecule NNMT inhibitor that helps preserve nicotinamide for NAD+ production, especially inside fat (adipose) tissue, where NAD+ production relies heavily on the salvage pathway and NNMT can become a major drain. It’s framed as most useful for people with metabolic dysfunction tied to excess body fat. Published 1 Mar 2026 6 min read Reference-backed All content is for educational and research reference purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. [Read our full disclosure](https://peptidesupermarket.co.uk/disclosure). # 5-Amino-1MQ — where it fits, how it works, and why most dosing advice online doesn’t make pharmacological sense ## Quick take 5-Amino-1MQ is positioned as a **small molecule NNMT inhibitor** that helps **preserve nicotinamide for NAD+ production**, especially inside **fat (adipose) tissue**, where NAD+ production relies heavily on the salvage pathway and NNMT can become a major drain. It’s framed as most useful for **people with metabolic dysfunction tied to excess body fat**, because that’s where **NNMT overexpression** becomes the problem you’re actually correcting. --- ## The energy system you need to understand first Your mitochondria make **ATP** by running electrons through the electron transport chain. **NAD+** is described as the shuttle that makes this possible: - it picks up electrons from food-derived metabolism - carries them into the electron transport chain - electrons moving through the chain pump protons across the membrane - that gradient drives ATP production - NAD+ becomes **NADH** after dropping off electrons - NADH is converted back into NAD+ so the cycle can repeat If NAD+ availability drops, electron shuttling becomes inefficient → ATP output falls → energy drops. --- ## The NAD+ salvage pathway Most NAD+ production is described as coming through the **salvage pathway**: - you take in **nicotinamide (vitamin B3 form)** - the body recycles it back into NAD+ This pathway is described as responsible for **~80%** of NAD+ production, so protecting it matters. --- ## What NNMT is, and why it becomes a problem **NNMT** is described as a normal clearance enzyme: - it takes nicotinamide and **methylates it into a waste product** - that waste gets excreted Under normal conditions, that doesn’t matter much because tissues like the liver have multiple ways to generate NAD+. The problem is framed as being most important in **adipose tissue**: - fat cells rely heavily on the salvage pathway for NAD+ - NNMT is described as the **only major catabolic enzyme for nicotinamide in fat** - when NNMT is **overexpressed in adipose tissue** (especially with obesity), it creates a drain on nicotinamide that fat cells need for NAD+ So you end up with two competing fates for the same input: - nicotinamide → **NAD+** (energy support) - nicotinamide → **waste** (via NNMT) Pricing for **5-Amino-1MQ**can vary, so we’ve put together a UK price comparison hub here: [Compare peptide prices UK.](https://peptidesupermarket.co.uk/compare-peptide-prices-uk) --- ## The vicious cycle in fat tissue The mechanism is laid out as a self-reinforcing loop: 1. Obesity increases **NNMT expression** in fat 2. Higher NNMT activity drains nicotinamide away from NAD+ salvage 3. Fat-cell NAD+ drops 4. Fat burning becomes less efficient and fat storage becomes easier 5. More fat tissue → even more NNMT expression That’s the cycle 5-Amino-1MQ is positioned to interrupt. --- ## What 5-Amino-1MQ does 5-Amino-1MQ is framed as the compound that **plugs the leak**: - it **blocks NNMT** - by inhibiting NNMT in adipose tissue, it reduces nicotinamide waste - that shifts the balance back toward **NAD+ production** So instead of losing nicotinamide to clearance, more of it becomes available to the salvage pathway. --- ## What the animal results were described to show In the animal model described: - mice treated with 5-Amino-1MQ lost significant body fat **without changing food intake** - **~35% reduction in body mass** - **~30% decrease in fat cell size** - fat loss was attributed to **increased energy expenditure**, not appetite suppression The important qualifier: the model referenced was **diet-induced obese mice**, meaning NNMT was already elevated and the intervention was correcting a dysfunction that was present. --- ## Who this is actually for The target population is framed by the mechanism: - NNMT overexpression is described as correlating more with **body fat** than with aging - obese / metabolically dysfunctional individuals are more likely to have the “NNMT drain” that needs correcting - lean, metabolically healthy individuals likely have adipose NNMT closer to baseline → less dysfunction to fix So the compound is framed as being more of a **metabolic dysfunction tool** than a “lean optimization” tool. --- ## The dosing problem The dosing landscape is described as chaotic and inconsistent, and the spread is massive: - translated mouse dosing (via allometric scaling) is described as roughly **~400 mg/day human equivalent** - other suggestions: **50–150 mg/day oral** - other suggestions: **50–100 mg/day subcutaneous** - microdose suggestions: **150–600 micrograms/day** That’s described as roughly a **2,500× difference** between microdose levels and what the animal-to-human translation implies. There’s also a key limitation stated: **no human trial data**. --- ## IC50 coverage — the logic used to evaluate dosing The dosing argument is framed using **IC50 coverage**: - to get meaningful effect, you need enough concentration to inhibit at least **~50%** of the target enzyme - below that threshold, inhibition is too small to matter To estimate what might achieve that, the comparison used is a structurally similar small molecule: - **metformin** is used as the closest analog (small, positively charged, similar bioavailability and half-life) From that comparison, the framing is: - **50–150 mg/day oral** plausibly reaches partial inhibition - **400–600 mg/day** aligns with near-complete inhibition and matches the translated mouse dose range Microdosing is framed as being nowhere close: - a **150 microgram/day** dose is described as **~400× below** what would be needed for ~50% inhibition - the conclusion presented is: you can’t “outsmart pharmacology”—either the concentration is effective or it isn’t --- ## The “NAD+ support” microdose argument — and why it’s rejected The microdose claim is sometimes framed as “NAD+ support” rather than fat loss, but the counter-logic presented is: - the enzyme that converts nicotinamide toward NAD+ salvage is described as having **far higher affinity** for nicotinamide than NNMT - nicotinamide is said to preferentially flow toward NAD+ under normal conditions - NNMT only becomes a meaningful drain when it’s **massively overexpressed** (again pointing back to obesity / excess adipose tissue) - the lowest concentration linked to NAD+ increases in the data referenced is described as **~1,000× higher** than microdose exposure So the practical conclusion given is: - if the goal is NAD+ support, direct precursors (like NMN) or NAD+ strategies make more sense than microdosing an inhibitor that can’t reach meaningful tissue concentration If your goal is simply to compare **5-Amino-1MQ**prices (UK), use our dedicated comparison page: [Compare peptide prices UK.](https://peptidesupermarket.co.uk/compare-peptide-prices-uk) --- ## Why microdose protocols exist The explanation given is economics: - at **150 micrograms/day**, a small vial lasts a long time - at multi-milligram effective dosing, it lasts only a couple days - true effective dosing becomes financially unrealistic for many people outside funded trials - so people default to what they can afford and then rely on anecdotal reports --- ## Practical dosing guidelines described Key practical point: **5-Amino-1MQ is a small molecule**, not a peptide, and it can be taken orally. - Oral bioavailability is described as **~38%** - Oral dosing framed as plausible for partial inhibition: **~50–100 mg/day** - Subcutaneous dosing framed as effective at lower amounts because it bypasses digestion: **~50–100 mg/day** And the hard line stated: - microdoses “don’t make sense” and aren’t expected to produce results. --- ## Where it fits in a protocol It’s framed as a “support” add-on in NAD+-focused stacks: - If you’re using **NAD+ and repair support**, adding 5-Amino-1MQ is positioned as a way to reduce NNMT drain and preserve nicotinamide for NAD+ salvage. - If you’re using **MOTS-C + NAD+ optimization**, the same logic applies. The recurring filter stays the same: - people most likely to benefit are those with **metabolic dysfunction tied to excess body fat** - lean, metabolically healthy people are less likely to have the NNMT overexpression problem in adipose tissue --- ## Final take 5-Amino-1MQ is framed as: - a real compound with a real mechanism - especially relevant when NNMT overexpression in adipose tissue is part of the metabolic dysfunction picture But the big warning is dosing: - the effective-dose logic is framed around enzyme inhibition thresholds - and most online protocols—especially microdosing—are positioned as inconsistent with basic pharmacology And the foundation point stays consistent: - these compounds don’t replace training, nutrition, sleep, and recovery habits—they amplify a solid base. Price Comparison ### Compare 5-Amino 1MQ prices across the UK Side-by-side prices from every trusted UK supplier stocking 5-Amino 1MQ. [Compare prices](https://peptidesupermarket.co.uk/peptide/5-amino-1mq) [All articles](https://peptidesupermarket.co.uk/research) Share copied = false, 2000)" aria-label="Copy link" class="w-8 h-8 rounded-full bg-bg-light hover:bg-primary hover:text-white text-text-muted flex items-center justify-center transition-colors cursor-pointer relative"> ### Featured Peptide #### 5-Amino 1MQ Experimental small-molecule compound investigated for its potential effects on fat metabolism, cellular energy regulation and metabolic health. [Compare prices](https://peptidesupermarket.co.uk/peptide/5-amino-1mq) ### More Guides [Browse all guides](https://peptidesupermarket.co.uk/research/category/guides) Keep Reading ## Related articles Guides ### AICAR Peptide Guide: Mechanism, Cost and Safety AICAR is discussed for endurance and metabolic research, but its high cost, anti-doping status and unresolved safety questions make it a highly specialised compound. 7 min read [AICAR Peptide Guide: Mechanism, Cost and Safety](https://peptidesupermarket.co.uk/research/aicar-peptide-guide-mechanism-cost-and-safety) Guides ### AHK-Cu Peptide Guide: Skin, Hair and Research Use AHK-Cu is a copper-binding tripeptide discussed for skin quality, tissue repair signalling and scalp support. This guide explains how it compares with GHK-Cu and why safety matters. 8 min read [AHK-Cu Peptide Guide: Skin, Hair and Research Use](https://peptidesupermarket.co.uk/research/ahk-cu-peptide-guide-skin-hair-and-research-use) Guides ### HMG fertility guide: FSH, LH and how menotropins are discussed in research HMG, or human menopausal gonadotropin, is discussed in fertility research because it provides both FSH and LH activity. This guide explains the mechanism, comparisons and key cautions. 6 min read [HMG fertility guide: FSH, LH and how menotropins are discussed in research](https://peptidesupermarket.co.uk/research/hmg-fertility-guide-fsh-lh-and-how-menotropins-are-discussed-in-research) --- *Add `.md` to any page URL on peptidesupermarket.co.uk for its Markdown version. Index of the site: https://peptidesupermarket.co.uk/llms.txt - full text: https://peptidesupermarket.co.uk/llms-full.txt.*